Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a user experimenting with RU58841 for hair regrowth by ingesting it, which others find concerning. There are mentions of potential side effects and comparisons to other treatments like minoxidil, finasteride, and flutamide.

Dutasteride mesotherapy, combined with peptides and exosomes, is being considered for hair loss treatment. One user suggests that oral finasteride or dutasteride mesotherapy may not be necessary if already taking oral dutasteride.

Pirfenidone is suggested to treat fibrosis and baldness by blocking inflammation markers and reducing collagen. It is also available as a gel for scar removal.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

Mesotherapy for hair loss, including treatments like finasteride and dutasteride, is discussed, with some users reporting pain and mixed results. Alternatives like PRP injections and topical treatments such as minoxidil, RU58841, and tretinoin are also mentioned as effective options.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.

The user is considering switching to topical finasteride or pyrilutamide to stabilize hair loss before a hair transplant, currently using oral minoxidil and finasteride. Suggestions include sticking to the current regimen as it is already potent, and caution against using pyrilutamide from unreliable sources.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

The user has been using 2.5 mg minoxidil, 0.5 mg Dutasteride, and 10 mg Zinc daily for 4 months and noticed hair regrowth. They switched from finasteride to Dutasteride after finasteride was ineffective.

User asks if HMI 115 hasn't done phase 1 for AGA in humans. Conversation includes treatments Min, Fin, and RU.

The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.

The user shared their successful hair regrowth experience using Dutas, oral and topical minoxidil, vitamin D3, zinc, biotin, a laser cap, natural shampoos, ketoconazole shampoo, retinoic acid lotion, and mesotherapy. They reported no side effects and significant improvement in hair thickness and color over six months.

Breezula, a new topical hair loss treatment, is expected to be expensive, with an estimated cost of €300 per month, making it less accessible compared to cheaper alternatives like finasteride. Some users discuss the potential for cheaper generics from countries like China and India, while others debate the effectiveness and pricing strategy of Breezula compared to other treatments like minoxidil and RU58841.

The user experiences severe side effects from finasteride and dutasteride, including low libido and anxiety, and is currently using oral minoxidil despite shortness of breath. They are seeking alternative treatments for hair loss, having tried pyrilutamide, fluridil, and RU58841 with no success, and are considering future treatments or a hair transplant.

Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

A 31-year-old male experienced side effects from various hair loss treatments, including finasteride and dutasteride, and is considering mesotherapy with dutasteride as a last resort. Another user tried mesotherapy for four months without significant change but experienced no side effects.

A 49-year-old male switched from Finasteride to Dutasteride 2.5 mg daily, along with oral Minoxidil 5 mg, resulting in significant hair regrowth and stopping hair loss after six months. Despite initial side effects like adrenaline spikes and urinary issues, the user is satisfied with the results and plans to continue the treatment.

Dutasteride mesotherapy in women with metabolic syndrome accelerated hair loss after initial regrowth, while women without metabolic syndrome saw continuous regrowth. The user with mild insulin resistance is hesitant to try topical dutasteride and seeks experiences from others with insulin resistance.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

A user ordered pyrilutamide (KX826) to stop hair loss and is seeking success stories. Replies indicate that it's too early to evaluate the product's effectiveness, as it takes several months to see results.

The conversation discusses the effectiveness of Dutasteride mesotherapy for hair loss treatment in Germany. The user is considering trying it and seeks opinions from others who have experience with it.